IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management frames Scent’s recovery around a long-running initiative to “get the balance right” and to invest in R&D and grow market share back within the Scent businesses. 1
Erik states that roughly 2.5 years ago the R&D pipeline “was not what it should have been”, and that today IFF believes it has a “very strong R&D capability,” a great R&D team, leading-edge perfumers, and a pipeline of molecules and delivery systems. 2 This is the clearest direct articulation that the recovery is supported by improved product development capacity rather than only near-term demand swings. 2
In Fine Fragrance, management acknowledges that the Middle East conflict creates “noise”/volatility, and that they have been actively managing the uncertainty. 1 In Q2 specifically, IFF notes that they expected Fine Fragrance to be down mid-single digits but it finished slightly positive, despite that uncertainty. 3 The recovery therefore includes both execution to manage disruption and an expected reversion pattern as the comps normalize. 3
For Consumer Fragrance, management emphasizes that the team is rebuilding R&D capability and the go-to-market approach with customers and targeting market share gains. 4 This is explicitly tied to the recovery mechanism (share/innovation capability), not just macro conditions. 4
While your question focuses on Fine/Consumer Fragrance, Scent’s overall recovery also depends on Fragrance Ingredients performance because it contributed materially to the segment’s results. 5 In Q2, Scent sales grew 8%, with Fragrance Ingredients growing north of 20% (including a favorable year-ago comparison) while IFF also describes strategic use of the synthetics portfolio to capture sales amid macro/supply chain disruption and higher Brent crude. 35 Importantly, management expects Fragrance Ingredients to normalize in the second half and shift toward higher value-added ingredients (away from traditional synthetics). 43 This supports the “recovery” story as progress on both demand capture and mix. 43
Management’s guidance for Fine Fragrance is that it will be “a little bit softer in Q3” but “a stronger Q4.” 4 On a second-half basis, Fine Fragrance is expected to be in the mid-single-digit growth range. 4 Management also explains the logic: they cite a ~20% year-over-year comp in Q3 last year (i.e., a tough comparison), but still describe the direction as trending correctly and highlight a recovery into Q4. 3
Additionally, the earlier disclosure reinforces that Q2 finished slightly positive even with Middle East volatility (helping establish the baseline for later quarters). 3
For Consumer Fragrance, management expects growth to remain around the low single-digit range going forward. 4 They state that Q2 was “a really good Q2 at a high single-digit number” but they expect it to normalize to a low single-digit pace on a go-forward basis. 4 This implies that Consumer Fragrance’s 2H evolution is less about a sharp sequential step-up and more about normalization after an above-trend quarter. 4
Management attributes Consumer Fragrance support to the rebuilding of R&D capability and go-to-market approach and the drive for market share gains. 4 For Fine Fragrance, the emphasis is on managing Middle East uncertainty through the year and then benefiting as Q4 recovery/less severe volatility shows through. 3
IFF’s CEO-level commentary ties progress to a concrete R&D pipeline improvement over ~2.5 years: moving from falling behind to having strong R&D capability, leading-edge new Fine and Consumer fragrances, and an expanded pipeline of molecules and delivery systems. 2 This provides the foundation for supporting 2027 because it indicates that R&D execution and pipeline quality are being strengthened ahead of that time horizon. 2
Management states that they are addressing gaps and strengthening strengths in R&D and are “making really good progress,” while still not claiming the work is finished. 2 That “address gaps + strengthen strengths” framing is consistent with an R&D plan intended to improve competitiveness into 2027, rather than just deliver near-term reformulations. 2
While your question asks about R&D for 2027, management also gives a time horizon about readiness and competitiveness: on the Fragrance Ingredients side, management says the shift to higher-value natural products is underway, and although it won’t fully show “in the second half of this year,” they believe they will have a really strong competitive position as they go into next year and the year after. 4 Because their commentary groups Scent’s R&D capability building with overall Scent evolution into that later period, this supports the idea that R&D work is intended to translate into competitive advantage beyond 2026, including 2027. 42
The specific R&D outputs management highlights—molecules and delivery systems—are the kinds of elements typically used to support ongoing fragrance performance, differentiation, and costed scaling into later periods (including 2027). 2 Management also notes the existence of great perfumers developing leading-edge new Fine Fragrances and Consumer Fragrances. 2 This is the most direct statement in the excerpts about the operational content of the R&D plan. 2
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi